Camille Bedrosian
About Camille L. Bedrosian, M.D.
Independent director at Crinetics Pharmaceuticals since September 2020 (Class III; term through the 2027 annual meeting). Age 72. Currently Chief Medical Officer at Amylyx Pharmaceuticals (since November 2023). Former EVP/CMO at Ultragenyx (2018–2023; Strategic Development Advisor in 2023), SVP/CMO at Alexion (2008–2018), CMO at ARIAD (2002–2008), Clinical R&D at Wyeth/Genetics Institute (1997–2002), and faculty at Duke (1986–1997). Education: AB (Harvard), MS Biophysics (MIT), MD (Harvard Medical School) .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Ultragenyx Pharmaceutical | EVP & CMO; later Strategic Development Advisor | 2018–May/Nov 2023 | Led drug development/translational research programs . |
| Alexion Pharmaceuticals | SVP & CMO | 2008–2018 | Led development in complement-mediated rare diseases . |
| ARIAD Pharmaceuticals | VP & CMO | 2002–2008 | Built clinical organization; oncology focus . |
| Wyeth/Genetics Institute | Clinical R&D (Sr. Director Oncology/Hematology) | 1997–2002 | Clinical development leadership . |
| Duke University Medical Center | Fellow → Assistant Professor (Heme/Onc) | 1986–1997 | Academic clinical/oncology roles . |
External Roles
| Organization | Role | Since | Committees/Notes |
|---|---|---|---|
| Amylyx Pharmaceuticals (AMLX) | Chief Medical Officer | Nov 2023 | Executive officer role . |
| Rhythm Pharmaceuticals (RYTM) | Director | Dec 2020 | Governance & Nominating Committee member (appointed Dec 31, 2020) . |
Board Governance
- Independence: Board determined all directors other than CEO are independent; Dr. Bedrosian is an independent director (also confirmed at appointment) .
- Board/committee attendance: Board met 4x in 2024; each director attended ≥75% of board and committee meetings during their service in 2024 .
- Committee assignments (2024): Chair, Research & Development Committee (met 4x in 2024) ; Member, Nominating & Corporate Governance Committee (met 3x) ; Member, Global Therapeutics Strategy & Access Committee (established Sept 2024; met once) .
- Board structure: Classified board; Dr. Bedrosian is Class III with term expiring at 2027 annual meeting .
- Risk oversight context: Audit oversees financial/cybersecurity risks; Compensation assesses comp risk; regular board-level risk updates .
Fixed Compensation
| Component | FY2024 Amount |
|---|---|
| Fees Earned or Paid in Cash | $60,250 |
Director cash fee policy (effective June 7, 2024): $41,000 annual retainer; additional annual retainers—Board Chair $30,000; committee chairs (Audit $20,000; Comp $15,000; Nominating & Corporate Governance $10,000; Research & Development $15,000); committee members (Audit $10,000; Comp $7,500; Nominating & Corporate Governance $5,000; Research & Development $7,500) .
Performance Compensation
| Equity Award (FY2024) | Grant-Date Fair Value |
|---|---|
| Stock Awards (RSUs) | $152,014 |
| Option Awards | $341,750 |
| Total Equity Value | $493,764 |
- Director equity program design (effective June 7, 2024): Annual option grant value $350,000 and RSUs $150,000 for continuing directors (time-based vesting: earlier of first anniversary or next annual meeting; initial grants: options $525,000 + RSUs $225,000, vest over 3 years) .
- Performance metrics tied to director pay: None disclosed; director equity vests time-based (no performance conditions) .
Other Directorships & Interlocks
| Company | Role | Potential Interlocks/Notes |
|---|---|---|
| Rhythm Pharmaceuticals (RYTM) | Director; Gov/Nom Committee | Different therapeutic focus vs. CRNX (no interlock or related-party disclosure noted regarding CRNX) . |
| Amylyx Pharmaceuticals (AMLX) | CMO (executive role) | Executive role in neurology-focused biotech; no CRNX related-party transactions disclosed involving Dr. Bedrosian . |
At time of CRNX appointment (Sept 2020), company disclosed no Item 404(a) related-party transactions involving Dr. Bedrosian; Board determined independence .
Expertise & Qualifications
- Scientific/clinical leadership in rare disease development; prior CMOs at Alexion, ARIAD; oversight of global regulatory matters .
- Academic grounding in hematology/oncology; Harvard AB/MD and MIT MS in Biophysics .
- Committee leadership experience (chairs CRNX Research & Development Committee) .
Equity Ownership
| Ownership Detail | Amount | As-Of |
|---|---|---|
| Common shares beneficially owned | 9,400 | April 14, 2025 |
| Options exercisable within 60 days | 93,400 | April 14, 2025 |
| RSUs outstanding | 3,400 | Dec 31, 2024 |
| Options outstanding | 90,000 | Dec 31, 2024 |
- Stock ownership guidelines (adopted Feb 20, 2025): Non-employee directors must hold 3x annual cash retainer; five-year compliance window; must retain at least 50% of net shares from equity awards for one year until in compliance .
- Hedging/pledging: Prohibited for directors; also prohibits margining/short sales/derivative transactions in company stock .
- Compliance status: Guidelines newly adopted in Feb 2025; compliance measured annually over a five-year window .
Governance Assessment
-
Strengths
- Independent director with deep rare disease and regulatory expertise; chairs CRNX R&D Committee—directly relevant to pipeline strategy .
- Good engagement: board met 4x and each director ≥75% attendance in 2024; serves on multiple strategic committees (R&D chair; Nominating & Governance; Global Therapeutics Strategy & Access) .
- Pay alignment: Majority of director compensation in equity; program uses time-based RSUs/options with clear vesting; capped within plan limits .
- Alignment/controls: Newly adopted stock ownership guidelines (3x retainer), mandatory holding periods, and prohibitions on hedging/pledging strengthen alignment and risk control .
- Compensation governance: Independent consultants (Aon; Pearl Meyer) engaged; committee assessed no consultant conflicts in 2024 .
-
Watch items
- Time commitments: Concurrent roles (CRNX board/committee chair; Rhythm board; Amylyx CMO) could pose competing time demands; no attendance shortfalls disclosed in 2024 .
- Related-party/conflicts: No CRNX related-party transactions involving Dr. Bedrosian disclosed; continue monitoring given executive role at another biotech (no overlap disclosed) .
-
Shareholder sentiment (context signal): 2024 say‑on‑pay support was high (For 64,052,127; Against 1,745,589), indicating broad approval of compensation governance during the period .
Appendices
Committee Memberships and 2024 Meeting Counts
| Committee | Role | Meetings in 2024 |
|---|---|---|
| Research & Development | Chair | 4 |
| Nominating & Corporate Governance | Member | 3 |
| Global Therapeutics Strategy & Access | Member | 1 (established Sept 2024) |
Director Compensation (FY2024)
| Metric | FY2024 |
|---|---|
| Cash Fees | $60,250 |
| Stock Awards (RSUs) | $152,014 |
| Option Awards | $341,750 |
| Total | $554,014 |
Director Equity Holdings Detail
| Instrument | Quantity | Notes |
|---|---|---|
| RSUs outstanding (12/31/2024) | 3,400 | Outstanding at year-end . |
| Options outstanding (12/31/2024) | 90,000 | Outstanding at year-end . |
| Options exercisable within 60 days (4/14/2025) | 93,400 | Beneficial ownership footnote (exercisable or within 60 days) . |
| Common shares owned (4/14/2025) | 9,400 | Beneficial ownership footnote . |
Director Compensation Policy (Effective June 7, 2024)
| Role | Annual Retainer |
|---|---|
| Non‑Employee Director | $41,000 |
| Board Chair (additional) | $30,000 |
| Committee Chair – Audit | $20,000 |
| Committee Chair – Compensation | $15,000 |
| Committee Chair – Nominating & Governance | $10,000 |
| Committee Chair – Research & Development | $15,000 |
| Committee Member – Audit | $10,000 |
| Committee Member – Compensation | $7,500 |
| Committee Member – Nominating & Governance | $5,000 |
| Committee Member – Research & Development | $7,500 |
| Annual Equity (continuing directors) | Options $350,000; RSUs $150,000; time-based vesting |
Additional governance policies: Board prohibits hedging/pledging; publishes charters; communications protocols; diversity statistics disclosed (3 of 8 directors female) .